The company says it believes it will have a better chance of attracting long-term investors as a privately held business.
Based in Lund, Spago Nanomedical is developing Tumorad, a radionuclide therapy currently being evaluated in a Phase I study in patients with head and neck cancer. According to the company, the maximum tolerated dose has been established and clear tumour uptake has been observed in patients in the study.
BREAKING